Poor
Not Aligned
Patient Risk:
High
Summary
Several key dosing details for hepatic impairment are incorrect (Child-Pugh B regimen contradicted). Many additional safety/monitoring and drug-combination claims are not supported by the provided label excerpts.
Category Scores
Accurate Statements
No dose adjustment is needed for mild hepatic impairment (Child-Pugh A).
2.2 Dosage in Patients With Hepatic Impairment: No dosage adjustment warranted in mild hepatic impairment (Child Pugh A).
For severe hepatic impairment (Child-Pugh C), use the same reduced maintenance dose.
2.2 Dosage in Patients With Hepatic Impairment: In severe hepatic impairment (Child Pugh C), initial 100 mg followed by reduced maintenance dose 25 mg every 12 hours; caution and monitoring.
Unsupported Statements
Tigecycline requires dose adjustments in patients with moderate to severe hepatic impairment.
Label provided states no dosage adjustment in mild to moderate hepatic impairment (Child Pugh A and B); reduced dosing only for severe impairment (Child Pugh C).
Tigecycline is an IV glycylcycline antibiotic.
Not stated in the provided label excerpts.
Tigecycline has primary hepatic metabolism and biliary excretion.
Not stated in the provided label excerpts.
Dose adjustments are intended to prevent excessive tigecycline accumulation due to reduced clearance in advanced liver disease.
Rationale not described in provided excerpts.
In clinical trials, tigecycline showed higher overall mortality than comparators (4% vs 3%).
Boxed warning in provided excerpts describes an increase in all-cause mortality and gives a mortality risk difference of 0.6% with CI, but does not provide the specific 4% vs 3% figures in the provided text.
Discontinuation rates due to liver-related adverse events in clinical trials were low (around 1-2%).
No discontinuation-rate figures for liver-related adverse events in provided excerpts.
Use caution in decompensated cirrhosis because available data is limited.
Provided excerpts specify caution/monitoring for severe hepatic impairment (Child Pugh C) but do not mention 'decompensated cirrhosis' or 'data is limited.'
Tigecycline should be avoided in acute liver failure or end-stage liver disease without specialist oversight.
Not stated in provided label excerpts.
In acute liver failure or end-stage liver disease, tigecycline use carries risk of worsening hepatic encephalopathy or coagulopathy.
Provided excerpts discuss hepatic function worsening/hepatic failure and abnormal LFT monitoring, but do not mention hepatic encephalopathy or coagulopathy.
Liver function tests should be monitored frequently, especially in Child-Pugh B/C patients.
Label excerpt advises monitoring for evidence of worsening hepatic function and reduced dosing caution/monitoring in Child Pugh C, but does not specify 'frequently' nor explicitly 'especially in Child-Pugh B/C'.
Tigecycline is not recommended for pregnant patients with liver issues due to limited data.
Pregnancy section excerpt is not provided; no pregnancy guidance about 'liver issues' appears in provided excerpts.
Concomitant hepatotoxins (e.g., acetaminophen) increase risks with tigecycline.
Provided excerpt mentions multiple concomitant medications in some patients, but does not identify hepatotoxins or acetaminophen.
Eravacycline has no dose adjustment for Child-Pugh B/C.
Eravacycline is not discussed in provided label excerpts.
Meropenem or piperacillin-tazobactam has primary renal clearance and should be adjusted for kidney issues instead of liver issues.
No such drug interaction/pharmacokinetic guidance for meropenem or piperacillin-tazobactam appears in provided excerpts.
Daptomycin has minimal liver metabolism.
Not discussed in provided label excerpts.
Causality between tigecycline and hepatic adverse events is unclear.
Label excerpt for hepatic adverse effects does not state causality is unclear.
Contradictions
High
AI Statement
For moderate hepatic impairment (Child-Pugh B), use a 100 mg loading dose followed by 25 mg every 12 hours.
Label Reference
2.2 Dosage in Patients With Hepatic Impairment: No dosage adjustment warranted in mild to moderate hepatic impairment (Child Pugh A and B). The 100 mg then 25 mg q12h regimen is for severe hepatic impairment (Child Pugh C).
Important Omissions
Boxed warning instruction: Tigecycline should be reserved for use when alternative treatments are not suitable (and boxed warning mortality risk difference not numerically compared as intended by the label).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
High
The Child-Pugh B dosing regimen is contradicted by the label (incorrect dose reduction/loading for moderate impairment). Several other hepatic-safety related claims are unsupported or extrapolated beyond provided label text.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Incorrect dosing for Child-Pugh B (moderate hepatic impairment) versus label (no adjustment needed).
Suggested Improvement
Use label-consistent hepatic impairment dosing: no adjustment for Child-Pugh A/B; 100 mg initial then 25 mg q12h only for Child-Pugh C, with caution and monitoring. Limit other hepatic safety/monitoring and non-tigecycline drug statements to what is present in the provided label excerpts.